Long-term Safety and Efficacy Evaluation of Lunsekimig in Adult Participants With Chronic Rhinosinusitis With Nasal Polyps (CRSwNP) Who Completed a Previous Lunsekimig CRSwNP Study

Part of paid clinical trials in La Jolla, California.

Sponsor
Sanofi
Study ID
NCT06914908
Phase
PHASE2
Status
Enrolling By Invitation

Conditions

  • Chronic Rhinosinusitis With Nasal Polyps

Eligibility Criteria

Sex
ALL
Age
N/A - N/A
Healthy Volunteers
Not accepted

Interventions

  • lunsekimig — DRUG
    Pharmaceutical form: solution for injection Route of administration: subcutaneous
  • Mometasone furoate nasal spray (MFNS) — DRUG
    Pharmaceutical form: Intranasal spray Route of administration: intranasal

Study Details

This is a single-arm extension study to investigate the long-term safety, tolerability, and efficacy of lunsekimig in adult participants with inadequately controlled CRSwNP who have completed a previous lunsekimig CRSwNP clinical study (also referred to as the parent study ACT18207). The study duration will be up to approximately 56 weeks per participant, 52 weeks of treatment period, and 4 weeks of follow-up.

Key Dates

Start date
May 12, 2025
Status verified
May 2026
Primary completion
Jan 29, 2031
Completion
Jan 29, 2031

Study Design

Enrollment
64 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Lunsekimig
    Participant will receive lunsekimig subcutaneous (SC) every 4 weeks and intranasal mometasone furoate nasal spray (MFNS) daily for 52 weeks.

Primary Outcome Measure

Incidence of participants with treatment-emergent adverse events (TEAEs) including [ Time Frame: From baseline to end of study (approximately 56 weeks) ]

Locations (9)

Find similar trials in La Jolla, CA

Related Studies